Abstract
Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ovarian weight, cortical and stromal fibrosis. Imatinib mesylate is an anticancer agent that inhibits competitively several receptor tyrosine kinases (RTKs). RTKs play important roles in cell metabolism, proliferation, and apoptosis. In clinic, imatinib mesylate is also known as an anti-fibrotic medicine. In the present study, the impact of imatinib on the ovarian tissue was investigated by assessing ovarian tissue fibrosis in postnatal rat administered with or without imatinib for three days. Fibrosis in the ovarian tissue was determined by histology (Picrosirius and Masson's trichrome staining) and the protein expression of vimentin and alpha-smooth muscle actin (α-SMA). Furthermore, mRNA expression of Forkhead box transcription factor O1 and O3 (FOXO1 and FOXO3), which are markers of cell proliferation was quantified. A short-term exposure to imatinib showed to increase tissue fibrosis in ovaries. This was observed by Masson's trichrome staining. Exposure to imatinib led also to a down-regulation of vimentin protein expression and up-regulation mRNA expression of FOXO3. This may indicate a role of FOXO3 in ovarian tissue fibrosis in postnatal rat ovaries.
| Original language | English |
|---|---|
| Pages (from-to) | 133-138 |
| Number of pages | 6 |
| Journal | Reproductive Biology |
| Volume | 19 |
| Issue number | 2 |
| Early online date | 10 May 2019 |
| DOIs | |
| Publication status | Published - Jun 2019 |
Fingerprint
Keywords
- FOXO1
- FOXO3
- Imatinib
- Ovary
- Tissue fibrosis
Cite this
}
Imatinib mesylate does not counteract ovarian tissue fibrosis in postnatal rat ovary. / Asadi-Azarbaijani, Babak; Braber, Saskia; van Duursen, Majorie; Jahnukainen, Kirsi; Santos, Regiane; Oskam, Irma.
In: Reproductive Biology, Vol. 19, No. 2, 06.2019, p. 133-138.Research output: Contribution to Journal › Article › Academic › peer-review
TY - JOUR
T1 - Imatinib mesylate does not counteract ovarian tissue fibrosis in postnatal rat ovary
AU - Asadi-Azarbaijani, Babak
AU - Braber, Saskia
AU - van Duursen, Majorie
AU - Jahnukainen, Kirsi
AU - Santos, Regiane
AU - Oskam, Irma
PY - 2019/6
Y1 - 2019/6
N2 - Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ovarian weight, cortical and stromal fibrosis. Imatinib mesylate is an anticancer agent that inhibits competitively several receptor tyrosine kinases (RTKs). RTKs play important roles in cell metabolism, proliferation, and apoptosis. In clinic, imatinib mesylate is also known as an anti-fibrotic medicine. In the present study, the impact of imatinib on the ovarian tissue was investigated by assessing ovarian tissue fibrosis in postnatal rat administered with or without imatinib for three days. Fibrosis in the ovarian tissue was determined by histology (Picrosirius and Masson's trichrome staining) and the protein expression of vimentin and alpha-smooth muscle actin (α-SMA). Furthermore, mRNA expression of Forkhead box transcription factor O1 and O3 (FOXO1 and FOXO3), which are markers of cell proliferation was quantified. A short-term exposure to imatinib showed to increase tissue fibrosis in ovaries. This was observed by Masson's trichrome staining. Exposure to imatinib led also to a down-regulation of vimentin protein expression and up-regulation mRNA expression of FOXO3. This may indicate a role of FOXO3 in ovarian tissue fibrosis in postnatal rat ovaries.
AB - Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ovarian weight, cortical and stromal fibrosis. Imatinib mesylate is an anticancer agent that inhibits competitively several receptor tyrosine kinases (RTKs). RTKs play important roles in cell metabolism, proliferation, and apoptosis. In clinic, imatinib mesylate is also known as an anti-fibrotic medicine. In the present study, the impact of imatinib on the ovarian tissue was investigated by assessing ovarian tissue fibrosis in postnatal rat administered with or without imatinib for three days. Fibrosis in the ovarian tissue was determined by histology (Picrosirius and Masson's trichrome staining) and the protein expression of vimentin and alpha-smooth muscle actin (α-SMA). Furthermore, mRNA expression of Forkhead box transcription factor O1 and O3 (FOXO1 and FOXO3), which are markers of cell proliferation was quantified. A short-term exposure to imatinib showed to increase tissue fibrosis in ovaries. This was observed by Masson's trichrome staining. Exposure to imatinib led also to a down-regulation of vimentin protein expression and up-regulation mRNA expression of FOXO3. This may indicate a role of FOXO3 in ovarian tissue fibrosis in postnatal rat ovaries.
KW - FOXO1
KW - FOXO3
KW - Imatinib
KW - Ovary
KW - Tissue fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85065232406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065232406&partnerID=8YFLogxK
U2 - 10.1016/j.repbio.2019.03.003
DO - 10.1016/j.repbio.2019.03.003
M3 - Article
VL - 19
SP - 133
EP - 138
JO - Reproductive Biology
JF - Reproductive Biology
SN - 1642-431X
IS - 2
ER -